- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Gynecologic Cancers | Clinical
FDA Grants Priority Review to Cemiplimab for Recurrent/Metastatic Cervical Cancer
September 28, 2021
The FDA has accepted and granted priority review to the supplemental biologics license application for the PD-1 inhibitor cemiplimab-wlc for the treatment of patients with recurrent or metastatic cervical cancer whose disease progressed on or after chemotherapy.
FDA Approves Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer
September 20, 2021
Tisotumab vedotin has become the first and only approved antibody-drug conjugate for the treatment of recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.
Notable Activity in Recurrent/Metastatic Cervical Cancer Seen With Tisotumab Vedotin Plus Frontline Carboplatin and Second-/Third-Line Pembrolizumab
September 19, 2021
Tisotumab vedotin elicited significant responses without prohibitive toxicity in combination with carboplatin as frontline therapy, as well as in combination with pembrolizumab as second- or third-line therapy in patients with recurrent or metastatic cervical cancer.
In Cervical Cancer, The New Frontline SOC May Be Pembrolizumab/Chemo With or Without Bevacizumab
September 18, 2021
In patients with persistent, recurrent, or metastatic cervical cancer the addition of pembrolizumab to chemotherapy with or without bevacizumab significantly improved survival and response rates.
High Responses to Dostarlimab in Endometrial Cancer Linked to TMB-H Status
September 16, 2021
High responses to single-agent dostarlimab-gxly were seen in patients with endometrial cancer who had a high tumor mutational burden, irrespective of mismatch repair or microsatellite stability status.
Buparlisib Treatment Begins in Combination With AN0025 and Atezolizumab for Advanced Solid Tumors
September 09, 2021
The first patient with a locally advanced or metastatic solid tumor has been dosed with buparlisib in combination with A0025 with or without atezolizumab in a phase 1a clinical trial.
Gynecologic Oncology Study Shows Utility of Web-Based Health Information Collection
August 25, 2021
In an interview with Targeted Oncology, Melissa K. Frey, MD, discussed findings from implementing web-based health information collection of family history in patients with gynecologic cancers.
Perioperative Pembrolizumab Shows Activity in Advanced High-Grade Serous Carcinoma
August 19, 2021
In an interview with Targeted Oncology™, Isabelle Ray-Coquard, MD, PhD, discussed the NEOPEMBROV study in greater detail and the benefits of adding pembrolizumab to perioperative treatment for serous carcinoma deemed non-optimally resectable.
DUO-E Trial Explores 1L Durvalumab Maintenance With or Without Olaparib in Advanced/Recurrent Endometrial Cancer
August 15, 2021
In an interview with Targeted Oncology™, Shannon N. Westin, MD, MPH, FACOG, discussed the need for the DUO-E trial in the endometrial cancer space and the unique patient population the study will evaluate.
Westin Explains the Need for Novel Therapies in the Endometrial Cancer Space
August 14, 2021
Shannon Westin, MD, MPH, FACOG, a gynecologic oncologist at The University of Texas MD Anderson Cancer Center, discusses the use of durvalumab with or without olaparib for the treatment of endometrial cancers.